Abstract:[Objective] To explore the factors affecting the quality of life of patients with osteosarcoma after treatment. [Methods] A total of 80 patients who received treatments for osteosarcoma in our hospital from March 2020 to March 2022 were retrospectively analyzed. Three months after surgery, the patients were divided into good quality of life and poor quality of life group according to QLQ-C30 score of cancer patients' quality of life. Univariate comparison and logistic regression analysis were used to analyze the factors impacting quality of life of patients with osteosarcoma. [Results] All the 80 patients with osteosarcoma survived 3 months after treatments, with the survival rate of 100% (80/80). Of them, 23 patients with QLQ-C30 scores below 70 were classified as poor quality of life group, accounting for 28.8%, while the remaining 57 patients with scores ≥70 were classified as good quality of life group, accounting for 71.2%. As results of the univariate comparison, the poor group proved significantly inferior to the good group in terms of the nutritional status before treatment, pathological fracture, surgical mode of amputation, distant metastasis, sleep quality before treatment, family function and coping attitude (P<0.05). Regarding binary multifactor logistic analysis, the poor nutritional status (OR=6.667, 95% CI 2.241~19.830, P<0.001), clinical stage III (OR= 3.240, 95% CI 1.058~9.920, P<0.001), pathological fracture (OR=7.736, 95% CI 2.621~22.836, P<0.001), amputation (OR=6.505, 95% CI 2.243~18.868, P<0.001), distant metastasis (OR=20.611, 95% CI 5.523~76.913, P<0.001), poor sleep quality (OR=6.346, 95%CI 2.203~ 18.278, P<0.001), low level of family function (OR=5.436, 95%CI 1.893-15.608, P=0.002), improper coping alttitude (OR=6.682, 95% CI 2.206~20.370, P=0.002) were independent risk factors for poor quality of life in patients with osteosarcoma. [Conclusion] Poor nutritional status, clinical stage III, pathological fracture and amputation are risk factors affecting the quality of life of patients with osteosarcoma. Targeted intervention is needed to improve the quality of life of patients with osteosarcoma.